Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at evaluere sikkerheden, tolerabiliteten og effektiviteten af ​​XEN1101 ved svær depressiv lidelse (X-NOVA)

25. august 2026 opdateret af: Xenon Pharmaceuticals Inc.

En Proof-of-Concept, randomiseret, dobbeltblind, placebokontrolleret, multicenterundersøgelse for at evaluere sikkerheden, tolerabiliteten og effektiviteten af ​​XEN1101 ved svær depressiv lidelse

This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.

Studieoversigt

Detaljeret beskrivelse

The study is divided into 3 stages: Screening - up to 4 weeks duration; Treatment - 6 weeks duration; Follow-up - 4 weeks duration. The total study duration per subject is estimated to be approximately 14 weeks.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

168

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Anaheim, California, Forenede Stater, 92805
        • Advanced Research Center
      • Lafayette, California, Forenede Stater, 94549
        • Sunwise Clinical Research, LLC
      • Pico Rivera, California, Forenede Stater, 90660
        • California Neuropsychopharmacology Clinical Research Institute
      • Riverside, California, Forenede Stater, 92503
        • Artemis Institute for Clinical Research
      • San Diego, California, Forenede Stater, 92103
        • Artemis Institute for Clinical Research
    • Florida
      • Miami, Florida, Forenede Stater, 33014
        • Meridian International Research
      • Miami, Florida, Forenede Stater, 33125
        • Global Medical Institutes (GMI)
      • Miami, Florida, Forenede Stater, 33133
        • CCM Clinical Reseach Group, LLC
    • Georgia
      • Decatur, Georgia, Forenede Stater, 30030
        • i-Research, Atlanta
      • Marietta, Georgia, Forenede Stater, 30060
        • Psych Atlanta, PC
      • Savannah, Georgia, Forenede Stater, 31405
        • iResearch
    • Illinois
      • Elgin, Illinois, Forenede Stater, 60123
        • Revive Research Institute, Inc.
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89102
        • Altea Research
    • New Jersey
      • Marlton, New Jersey, Forenede Stater, 08009
        • Hassman Research Institute
      • Toms River, New Jersey, Forenede Stater, 08755
        • Bio Behavioral Health
    • New York
      • Cedarhurst, New York, Forenede Stater, 11516
        • Neurobehavioral Research, Inc. (NBR)
      • New York, New York, Forenede Stater, 10036
        • Manhattan Behavioral Medicine, PLLC
    • North Carolina
      • Raleigh, North Carolina, Forenede Stater, 27609
        • Richard M Weisler and Association
    • Texas
      • Dallas, Texas, Forenede Stater, 75231
        • FutureSearch Trials of Dallas, LP
      • Plano, Texas, Forenede Stater, 75093
        • AIM Trials

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  • Be properly informed of the nature and risks of the study and given written informed consent.
  • Male or female, aged 18 through 65 years (inclusive) with a body mass index (BMI) ≤35 kg/m².
  • Subject must meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for current MDD and currently in a moderate to severe major depressive episode (MDE), confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • Current MDE duration ≥2 months and <24 months at the time of screening.
  • Current illness severity that is at least moderate, defined as a score of ≥20 on the HAM-D17 at screening and on Day 1.
  • Score ≥20 on the SHAPS at screening and on Day1.
  • Must be willing to comply with the study protocol for the full term of the study.

Key Exclusion Criteria:

  • A primary psychiatric diagnosis other than MDD as defined by DSM-5 (comorbid anxiety disorders [including agoraphobia, generalized anxiety disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), and panic disorder] are allowed).
  • Concomitant use of antidepressants and/or other disallowed pharmacotherapy (including benzodiazepines).
  • History of schizophrenia or other psychotic disorder, MDD with psychotic features, bipolar I or II disorder, or MDD with mixed features.
  • History of non-response to >1 antidepressant drug due to lack of efficacy in the current MDE.
  • Failing >3 antidepressant drug trials, for any reason, in the current MDE.
  • History of non-response to electroconvulsive therapy (ECT) in the past 10 years.
  • Active suicidal plan/intent in the past 6 months, or more than 1 lifetime suicide attempt.
  • Females who are pregnant, breastfeeding, or planning to become pregnant during the first administration of study drug until 3 months after the last dose of study drug.
  • Meets criteria for a substance use disorder within the past 12 months, with the exception of tobacco use, and/or has a positive urine toxicology screen for drugs of abuse.
  • Any medical condition or personal circumstance that, in the opinion of the investigator, exposes the subject to unacceptable risk by participating in the study or prevents adherence to the protocol.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: XEN1101 10 mg

During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 10 mg, orally with food, per day

XEN1101 oral capsule

Eksperimentel: XEN1101 20 mg

During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 20 mg, orally with food, per day

XEN1101 oral capsule

Placebo komparator: placebo

During the double blind treatment period (42 days), subjects will take 1 capsule of placebo, orally with food, per day

Placebo capsule

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score.
Tidsramme: From baseline to end of treatment (Week 6).

Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated, 10-item scale used to assess the severity of depressive symptoms. Each item is scored from 0 (normal/absent) to 6 (severe), yielding a total score ranging from 0 to 60, with higher scores indicating greater depression severity.

MADRS total score change from baseline at week 6.

From baseline to end of treatment (Week 6).

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Snaith-Hamilton Pleasure Scale (SHAPS) Score.
Tidsramme: From baseline to end of treatment (Week 6).

Snaith-Hamilton Pleasure Scale (SHAPS) is a validated 14-item self-report questionnaire commonly used to assess anhedonia (reduced ability to experience pleasure). Each of the 14 items is rated from 1 (strongly agree) to 4 (strongly disagree). Total scores range from 14 to 56, with higher scores indicating greater levels of anhedonia.

SHAPS total score change from baseline at week 6

From baseline to end of treatment (Week 6).
Change in Beck Anxiety Inventory (BAI) Score.
Tidsramme: From baseline to end of treatment (Week 6).

Beck Anxiety Inventory (BAI) is a 21-item self-report questionnaire used to assess the severity of anxiety symptoms. Each item is scored on a scale from 0 (not at all) to 3 (severely), yielding a total score ranging from 0 to 63, with higher scores indicating greater anxiety severity.

BAI total score change from baseline at week 6

From baseline to end of treatment (Week 6).

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Study Director, Xenon Pharmaceuticals Inc.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. maj 2022

Primær færdiggørelse (Faktiske)

18. september 2023

Studieafslutning (Faktiske)

16. oktober 2023

Datoer for studieregistrering

Først indsendt

11. maj 2022

Først indsendt, der opfyldte QC-kriterier

11. maj 2022

Først opslået (Faktiske)

17. maj 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner